Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Certification | 2 | 2017 | 45 | 0.680 |
Why?
|
| Pancreas Transplantation | 7 | 2021 | 16 | 0.670 |
Why?
|
| General Surgery | 2 | 2017 | 47 | 0.660 |
Why?
|
| Test Taking Skills | 1 | 2017 | 3 | 0.570 |
Why?
|
| Internship and Residency | 2 | 2017 | 206 | 0.550 |
Why?
|
| Clinical Competence | 1 | 2017 | 210 | 0.490 |
Why?
|
| Kidney Transplantation | 4 | 2021 | 120 | 0.410 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2022 | 17 | 0.380 |
Why?
|
| Organ Transplantation | 4 | 2021 | 30 | 0.360 |
Why?
|
| Liver Transplantation | 4 | 2014 | 65 | 0.340 |
Why?
|
| Tissue and Organ Procurement | 4 | 2009 | 29 | 0.270 |
Why?
|
| Educational Measurement | 2 | 2017 | 53 | 0.260 |
Why?
|
| Graft Rejection | 4 | 2009 | 63 | 0.260 |
Why?
|
| Aneurysm | 1 | 2022 | 10 | 0.200 |
Why?
|
| Arteriovenous Fistula | 1 | 2022 | 11 | 0.200 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 12 | 0.190 |
Why?
|
| Renal Dialysis | 3 | 2022 | 108 | 0.190 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 51 | 0.190 |
Why?
|
| Graft Survival | 6 | 2014 | 90 | 0.180 |
Why?
|
| Adult | 15 | 2020 | 7448 | 0.180 |
Why?
|
| Surgical Instruments | 1 | 2020 | 21 | 0.180 |
Why?
|
| Health Care Costs | 1 | 2020 | 66 | 0.170 |
Why?
|
| Suture Techniques | 1 | 2020 | 150 | 0.170 |
Why?
|
| Humans | 22 | 2022 | 26286 | 0.150 |
Why?
|
| Male | 16 | 2020 | 14162 | 0.150 |
Why?
|
| Intestines | 2 | 2008 | 94 | 0.150 |
Why?
|
| Retrospective Studies | 10 | 2022 | 3367 | 0.150 |
Why?
|
| United States | 4 | 2017 | 1990 | 0.140 |
Why?
|
| Female | 15 | 2020 | 14539 | 0.140 |
Why?
|
| Treatment Outcome | 10 | 2022 | 3391 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2017 | 125 | 0.140 |
Why?
|
| Simulation Training | 1 | 2017 | 38 | 0.140 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 73 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 126 | 0.130 |
Why?
|
| Curriculum | 1 | 2017 | 140 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2017 | 151 | 0.130 |
Why?
|
| Time Factors | 5 | 2022 | 1391 | 0.120 |
Why?
|
| Liver Cirrhosis | 1 | 2014 | 42 | 0.120 |
Why?
|
| Middle Aged | 13 | 2020 | 8601 | 0.110 |
Why?
|
| Catheter Obstruction | 1 | 2013 | 2 | 0.110 |
Why?
|
| Angioplasty, Balloon | 1 | 2013 | 13 | 0.110 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2013 | 17 | 0.110 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2013 | 10 | 0.110 |
Why?
|
| Catheterization, Central Venous | 1 | 2013 | 34 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 151 | 0.100 |
Why?
|
| Stents | 1 | 2013 | 76 | 0.100 |
Why?
|
| Liver | 2 | 2009 | 123 | 0.100 |
Why?
|
| Vascular Patency | 2 | 2022 | 12 | 0.100 |
Why?
|
| Transplantation, Homologous | 2 | 2009 | 287 | 0.100 |
Why?
|
| Immunosuppressive Agents | 2 | 2009 | 124 | 0.090 |
Why?
|
| Child | 6 | 2009 | 1236 | 0.090 |
Why?
|
| Stomach | 1 | 2009 | 13 | 0.090 |
Why?
|
| Vascular Surgical Procedures | 1 | 2009 | 23 | 0.080 |
Why?
|
| Living Donors | 1 | 2009 | 6 | 0.080 |
Why?
|
| Leucine | 1 | 2009 | 11 | 0.080 |
Why?
|
| Gastric Fistula | 1 | 2009 | 4 | 0.080 |
Why?
|
| Intestinal Fistula | 1 | 2009 | 4 | 0.080 |
Why?
|
| Colonic Diseases | 1 | 2009 | 9 | 0.080 |
Why?
|
| Diabetic Nephropathies | 1 | 2009 | 22 | 0.080 |
Why?
|
| Hypoglycemia | 1 | 2009 | 12 | 0.080 |
Why?
|
| Pancreatectomy | 1 | 2008 | 8 | 0.080 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2008 | 4 | 0.080 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2008 | 10 | 0.080 |
Why?
|
| Organ Preservation Solutions | 1 | 2008 | 1 | 0.080 |
Why?
|
| Carcinoma, Papillary | 1 | 2008 | 17 | 0.080 |
Why?
|
| Colon | 1 | 2009 | 137 | 0.080 |
Why?
|
| Menorrhagia | 1 | 2008 | 3 | 0.080 |
Why?
|
| Aged | 9 | 2020 | 8765 | 0.080 |
Why?
|
| Program Development | 1 | 2008 | 61 | 0.080 |
Why?
|
| Hysterectomy | 1 | 2008 | 19 | 0.080 |
Why?
|
| Cystic Fibrosis | 1 | 2007 | 9 | 0.070 |
Why?
|
| Lung Transplantation | 1 | 2007 | 13 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2007 | 126 | 0.070 |
Why?
|
| Laparoscopy | 1 | 2008 | 160 | 0.070 |
Why?
|
| Tissue Donors | 2 | 2021 | 72 | 0.070 |
Why?
|
| Adolescent | 5 | 2009 | 2080 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 2 | 2002 | 67 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2009 | 162 | 0.060 |
Why?
|
| Survival Analysis | 3 | 2014 | 235 | 0.050 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2002 | 11 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2009 | 593 | 0.050 |
Why?
|
| Waiting Lists | 2 | 2014 | 14 | 0.050 |
Why?
|
| Vascular Diseases | 1 | 2002 | 43 | 0.050 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2022 | 18 | 0.050 |
Why?
|
| Glucuronidase | 1 | 2002 | 10 | 0.050 |
Why?
|
| Esophagectomy | 1 | 2002 | 21 | 0.050 |
Why?
|
| Carcinoma | 1 | 2002 | 60 | 0.050 |
Why?
|
| Esophageal Neoplasms | 1 | 2002 | 44 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2021 | 21 | 0.050 |
Why?
|
| Pancreas | 1 | 2021 | 28 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2002 | 123 | 0.050 |
Why?
|
| Cost Savings | 1 | 2020 | 30 | 0.050 |
Why?
|
| Risk Factors | 2 | 2022 | 2265 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 126 | 0.040 |
Why?
|
| Kidney | 1 | 2021 | 156 | 0.040 |
Why?
|
| Incidence | 1 | 2021 | 716 | 0.040 |
Why?
|
| Postoperative Complications | 2 | 2020 | 869 | 0.040 |
Why?
|
| Insulin | 2 | 2008 | 76 | 0.040 |
Why?
|
| Infant | 2 | 2008 | 520 | 0.030 |
Why?
|
| Aged, 80 and over | 4 | 2009 | 4675 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 127 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 1738 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2009 | 419 | 0.030 |
Why?
|
| Young Adult | 2 | 2009 | 1886 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2014 | 333 | 0.030 |
Why?
|
| Probability | 2 | 2002 | 85 | 0.020 |
Why?
|
| Reoperation | 2 | 2008 | 879 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2002 | 314 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2013 | 482 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 1074 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 2009 | 26 | 0.020 |
Why?
|
| Prognosis | 2 | 2002 | 758 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2009 | 12 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2009 | 53 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 2009 | 39 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 170 | 0.020 |
Why?
|
| Raffinose | 1 | 2008 | 1 | 0.020 |
Why?
|
| Procaine | 1 | 2008 | 2 | 0.020 |
Why?
|
| Potassium Chloride | 1 | 2008 | 5 | 0.020 |
Why?
|
| Amylases | 1 | 2008 | 4 | 0.020 |
Why?
|
| Glutathione | 1 | 2008 | 23 | 0.020 |
Why?
|
| Mannitol | 1 | 2008 | 12 | 0.020 |
Why?
|
| Allopurinol | 1 | 2008 | 5 | 0.020 |
Why?
|
| Adenosine | 1 | 2008 | 8 | 0.020 |
Why?
|
| Indiana | 1 | 2008 | 15 | 0.020 |
Why?
|
| Lipase | 1 | 2008 | 5 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2009 | 99 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 29 | 0.020 |
Why?
|
| Rituximab | 1 | 2008 | 50 | 0.020 |
Why?
|
| Glucose | 1 | 2008 | 48 | 0.020 |
Why?
|
| Fallopian Tubes | 1 | 2008 | 3 | 0.020 |
Why?
|
| Pneumoperitoneum, Artificial | 1 | 2008 | 3 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 33 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2008 | 24 | 0.020 |
Why?
|
| Ureter | 1 | 2008 | 18 | 0.020 |
Why?
|
| Cadaver | 1 | 2009 | 370 | 0.020 |
Why?
|
| Biopsy | 1 | 2008 | 200 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 192 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 679 | 0.020 |
Why?
|
| Endoscopy | 1 | 2008 | 176 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2009 | 629 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 936 | 0.020 |
Why?
|
| Pancreatitis | 1 | 2002 | 19 | 0.010 |
Why?
|
| Medical Records | 1 | 2002 | 31 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2002 | 15 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 40 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2002 | 34 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2002 | 90 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2002 | 77 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 252 | 0.010 |
Why?
|
| Gene Expression | 1 | 2002 | 181 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 305 | 0.010 |
Why?
|
| Survival Rate | 1 | 2002 | 322 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 460 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 485 | 0.010 |
Why?
|